This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): NY-ESO-T, NY-ESO-1, NYESO-1, NY-ESO-1 T Cells, NY-ESO-1c259-modified T cells, GSK3377794, GSK 3377794, GSK-3377794, NY-ESO SPEAR
Adaptimmune develops T-cells expressing a modified T Cell Receptor that can be engineered to recognized different epitopes (antigens).
NY-ESO-1(C259) is an autologous genetically modified T cell that targets NY-ESO-1, a tumor antigen found in normal testes and various tumors.
GSK and Adaptimmune
In June 2014, Adaptimmune announced that it has entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialisation of its NY-ESO-1 programme.
Under the terms of the agreement, Adaptimmune will co-develop its NY-ESO-1 clinical programme and associated manufacturing optimisation work together with GSK. GSK will have an option on the NY-ESO-1 programme through clinical proof of concept, anticipated during 2016, and, on exercise, will assume full responsibility for the programme. The companies will also co-develop other TCR target programmes and collaborate on further optimization of engineered TCR products.
According to the agreed development plan, the deal could yield payments in excess of $350 million to Adaptimmune over the next seven years, with significant additional development and commercialisation payments becoming due in subsequent years if GSK exercises all its...See full deal structure in Biomedtracker
Partners: GlaxoSmithKline plc
Additional information available to subscribers only: